Bristol-Myers Squibb

Bristol-Myers Squibb
Share

Bristol-Myers Squibb

 •  March 28

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely...

Bristol-Myers Squibb

 •  March 24

First Immuno-Oncology agent to receive positive CHMP opinion for the treatment of an advanced form of head and neck cancer Positive opinion based on overall survival benefit demonstrated in the Phase 3 CheckMate -141 trial
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) has...

Bristol-Myers Squibb

 •  March 20

Builds upon initial 2014 alliance in oncology Includes up to eight additional targets in oncology and other therapeutic areas CytomX to receive $200 million upfront payment
Bristol-Myers Squibb Company (NYSE:BMY) and CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the...

Bristol-Myers Squibb

 •  March 6

Post-hoc Analyses from the ARISTOTLE Trial Featured in Late-Breaker and Poster Sessions Real-World Data Analyses Include Database Reviews of U.S. Medicare Patient Population
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that eight abstracts have been accepted for presentation at the American College of...

Bristol-Myers Squibb

 •  February 2

Approval based on CheckMate -275, in which Opdivo demonstrated an objective response rate of 19.6% (95% CI: 15.1-24.9; 53/270 patients) 1 Treatment with Opdivo resulted in responses across levels of PD-L1 expression (≥1% vs. Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo...

Bristol-Myers Squibb

 •  January 19

All First-line Lung Registrational Studies Continue
Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of data available at this time. In order to protect the integrity of ongoing...

Bristol-Myers Squibb

 •  January 19

Opdivo demonstrated a 37% reduction in the risk of death compared to placebo 12-month overall survival rates were 26.6% in Opdivo-treated patients compared to 10.9% in placebo-treated patients
Bristol-Myers Squibb Company (NYSE:BMY) announced today the results of ONO-4538-12 demonstrating Opdivo (nivolumab) significantly reduced the risk of death...

Bristol-Myers Squibb

 •  January 5

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase 1b/2 clinical studies in multiple myeloma and solid tumors including...

Bristol-Myers Squibb

 •  December 20, 2016

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust...

Bristol-Myers Squibb

 •  December 6, 2016

Objective response rate with Opdivo plus Yervoy was 25% and was 11% with Opdivo monotherapy; in the combination arm, three patients experienced a complete response Estimated two-year survival rate with the combination was 30% and was 17% with Opdivo monotherapy No new safety signals were observed with Opdivo and Opdivo plus Yervoy in this updated...